ALK-Abelló A/S (ALK-B.CO)

DKK 161.5

(5.56%)

Operating Income Summary of ALK-Abelló A/S

  • ALK-Abelló A/S's latest annual operating income in 2023 was 666 Million DKK , up 41.7% from previous year.
  • ALK-Abelló A/S's latest quarterly operating income in 2024 Q2 was 262 Million DKK , down -16.46% from previous quarter.
  • ALK-Abelló A/S reported an annual operating income of 470 Million DKK in 2022, up 60.96% from previous year.
  • ALK-Abelló A/S reported an annual operating income of 292 Million DKK in 2021, up 94.67% from previous year.
  • ALK-Abelló A/S reported a quarterly operating income of 262 Million DKK for 2024 Q2, down -16.46% from previous quarter.
  • ALK-Abelló A/S reported a quarterly operating income of 97 Million DKK for 2023 Q2, down -57.46% from previous quarter.

Annual Operating Income Chart of ALK-Abelló A/S (2023 - 2002)

Historical Annual Operating Income of ALK-Abelló A/S (2023 - 2002)

Year Operating Income Operating Income Growth
2023 666 Million DKK 41.7%
2022 470 Million DKK 60.96%
2021 292 Million DKK 94.67%
2020 150 Million DKK 2242.86%
2019 -7 Million DKK 90.28%
2018 -72 Million DKK 27.27%
2017 -99 Million DKK -120.67%
2016 479 Million DKK 15.42%
2015 415 Million DKK 57.2%
2014 264 Million DKK 142.2%
2013 109 Million DKK -42.02%
2012 188 Million DKK -37.12%
2011 299 Million DKK 55.73%
2010 192 Million DKK 9.71%
2009 175 Million DKK 10.06%
2008 159 Million DKK -27.06%
2007 218 Million DKK 311.32%
2006 53 Million DKK 2550.0%
2005 2 Million DKK 0.0%
2004 - DKK 0.0%
2003 - DKK 0.0%
2002 - DKK 0.0%

Peer Operating Income Comparison of ALK-Abelló A/S

Name Operating Income Operating Income Difference
Bavarian Nordic A/S 1.49 Billion DKK 55.527%
Genmab A/S 5.32 Billion DKK 87.484%
Gubra A/S -49.41 Million DKK 1447.714%
Novo Nordisk A/S 102.57 Billion DKK 99.351%
Orphazyme A/S -27.04 Thousand DKK 2463026.667%
Pharma Equity Group A/S -25.29 Million DKK 2733.14%
Zealand Pharma A/S -572.23 Million DKK 216.385%